The latest announcement is out from uniQure (QURE).
uniQure N.V. has announced a significant milestone with the FDA granting its gene therapy candidate, AMT-130, the Regenerative Medicine Advanced Therapy designation for treating Huntington’s disease. This development is noteworthy for investors as it highlights the company’s advancement in the biotechnology space and its potential impact on a challenging neurological condition.
Find detailed analytics on QURE stock on TipRanks’ Stock Analysis page.